TheraRadar
← Back
Data updated: Mar 29, 2026

NOSTRUM LABS

CardiovascularInfectious DiseaseDermatology
Generics

NOSTRUM LABS is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Dermatology.

1993
Since
7
Drugs
-
Trials
37
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

CIPROFLOXACIN HYDROCHLORIDE 2025-12-17
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
CIPROFLOXACIN HYDROCHLORIDE 2025-09-30
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 40%
2 drugs
Infectious Disease 20%
1 drugs
Dermatology 20%
1 drugs
Gastroenterology 20%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Infectious Disease, Dermatology, Gastroenterology
APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Gastroenterology
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
B BRAUN specialty
Infectious Disease, Dermatology, Cardiovascular
BAUSCH specialty
Dermatology, Cardiovascular, Gastroenterology